Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advaxis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10
Advaxis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advaxis Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Advaxis and Bristol-Myers Squibb Enter into Agreement 13
Amgen Forms Partnership with Advaxis 14
Advaxis Enters into Co-Development Agreement with Especificos Stendhal 15
Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 16
Advaxis Enters into Research Agreement with Sorrento Therapeutics 17
Advaxis Enters into Agreement with Merck 18
Advaxis Enters into Agreement with MedImmune 19
Licensing Agreements 20
OS Therapies Enters into Licensing Agreement with Advaxis 20
Sellas Life Sciences Enters into Licensing Agreement with Advaxis 21
Knight Therapeutics Enters into Licensing Agreement with Advaxis 22
Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 23
Aratana Therapeutics Enters into Licensing Agreement with Advaxis 24
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 26
Advaxis Enters Into Licensing Agreement With Global BioPharma For ADXS-HPV 28
Advaxis Enters Into Agreement With FusionVax To License ADXS-HPV In Asia 30
Equity Offering 31
Advaxis Raises USD20 Million in Public Offering of Shares and Warrants 31
Advaxis Plans to Raise up to USD250 in Public Offering of Securities 33
Advaxis Prices Public Offering of Shares for USD20 Million 34
Advaxis Raises USD30.3 Million in Private Placement of Shares 36
Advaxis Raises USD25 Million in Private Placement of Shares 37
Advaxis Raises USD61.2 Million in Public Offering of Shares 39
Advaxis Raises USD23 Million in Private Placement of Common Stock 41
Advaxis Raises USD17 Million in Private Placement of Shares 43
Advaxis Raises USD14 Million in Public Offering Of Shares 45
Advaxis Completes Public Offering Of Shares For US$26.5 Million 46
Advaxis Announces Private Placement Of Common Stock For US$10 Million 47
Advaxis Inc – Key Competitors 48
Advaxis Inc – Key Employees 49
Advaxis Inc – Locations And Subsidiaries 50
Head Office 50
Recent Developments 51
Financial Announcements 51
Sep 10, 2018: Advaxis reports fiscal 2018 third quarter financial results 51
Jun 07, 2018: Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results 53
Mar 12, 2018: Advaxis Announces Q1 Fiscal 2018 Financial Results 55
Dec 20, 2017: Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update 57
Sep 11, 2017: Advaxis Reports Business Update and Third Quarter 2017 Results 59
Corporate Communications 61
Jun 06, 2018: Advaxis Appoints Molly Henderson as Chief Financial Officer 61
Jul 06, 2017: Advaxis Announces Change in Leadership 62
Apr 19, 2017: Advaxis Appoints Anthony Lombardo as Chief Business Officer 63
Product News 64
Jun 01, 2017: Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis’ Clinical Trials 64
03/26/2018: Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018 65
03/12/2018: Advaxis Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI (Durvalumab) 66
01/29/2018: Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies 67
01/25/2017: New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported 68
Product Approvals 69
Jul 13, 2018: Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab 69
Feb 13, 2018: Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union 70
Mar 23, 2017: EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer 71
Clinical Trials 72
Apr 17, 2018: Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting 72
Feb 12, 2018: Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer 73
Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders 74
Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 75
May 18, 2017: Advaxis to Host Investor & Analyst Day on June 12 76
Mar 27, 2017: Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac 77
Mar 15, 2017: Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer 78
Feb 06, 2017: Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer 80
Jan 30, 2017: GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer 81
Other Significant Developments 82
Jul 10, 2018: Advaxis Provides Update on MAA Filing and ADXS-HOT Program 82
Jun 13, 2017: Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day 83
Jan 09, 2017: Advaxis Provides 2017 Business Outlook 86
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89
Advaxis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advaxis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advaxis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10
Advaxis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advaxis and Bristol-Myers Squibb Enter into Agreement 13
Amgen Forms Partnership with Advaxis 14
Advaxis Enters into Co-Development Agreement with Especificos Stendhal 15
Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 16
Advaxis Enters into Research Agreement with Sorrento Therapeutics 17
Advaxis Enters into Agreement with Merck 18
Advaxis Enters into Agreement with MedImmune 19
OS Therapies Enters into Licensing Agreement with Advaxis 20
Sellas Life Sciences Enters into Licensing Agreement with Advaxis 21
Knight Therapeutics Enters into Licensing Agreement with Advaxis 22
Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 23
Aratana Therapeutics Enters into Licensing Agreement with Advaxis 24
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 26
Advaxis Enters Into Licensing Agreement With Global BioPharma For ADXS-HPV 28
Advaxis Enters Into Agreement With FusionVax To License ADXS-HPV In Asia 30
Advaxis Raises USD20 Million in Public Offering of Shares and Warrants 31
Advaxis Plans to Raise up to USD250 in Public Offering of Securities 33
Advaxis Prices Public Offering of Shares for USD20 Million 34
Advaxis Raises USD30.3 Million in Private Placement of Shares 36
Advaxis Raises USD25 Million in Private Placement of Shares 37
Advaxis Raises USD61.2 Million in Public Offering of Shares 39
Advaxis Raises USD23 Million in Private Placement of Common Stock 41
Advaxis Raises USD17 Million in Private Placement of Shares 43
Advaxis Raises USD14 Million in Public Offering Of Shares 45
Advaxis Completes Public Offering Of Shares For US$26.5 Million 46
Advaxis Announces Private Placement Of Common Stock For US$10 Million 47
Advaxis Inc, Key Competitors 48
Advaxis Inc, Key Employees 49
List of Figures
Advaxis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advaxis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10